Mirtazapine for Parkinson's Disease Tremor
Mirtazapine is not a standard or evidence-based treatment for tremor in Parkinson's disease and should not be used for this indication. The FDA-approved indication for mirtazapine is major depressive disorder only, with no approval for movement disorders 1.
Why Mirtazapine Is Not Recommended for PD Tremor
Lack of Guideline Support
The most recent 2024 European Academy of Neurology/Movement Disorder Society guidelines for Parkinson's disease make no mention of mirtazapine as a treatment option for tremor 2. These guidelines clearly outline the evidence-based approach to PD tremor:
- First-line pharmacological treatment: Levodopa remains the most effective medication for PD tremor
- Second-line options: Dopamine agonists, anticholinergics (in young, cognitively intact patients), propranolol, and clozapine
- Advanced therapies: Deep brain stimulation (DBS) of STN, GPi, or VIM; MR-guided focused ultrasound (MRgFUS)
What the Evidence Actually Shows
While there are isolated case reports suggesting mirtazapine may help with psychosis and dyskinesia in PD 3, 4, 5, these are entirely different symptoms than tremor. One 2003 open-label study found mirtazapine "moderately effective" for L-dopa-induced dyskinesias 4, and a 2017 marmoset study showed reduction in psychosis-like behaviors 5. However, none of these studies specifically evaluated tremor as an outcome.
A 2016 consensus statement mentions mirtazapine only for insomnia and psychosis in PD—not tremor 6. The 2023 comprehensive review on pharmacological treatment of PD tremor does not include mirtazapine among recommended options 7.
Evidence-Based Approach to PD Tremor
Start with levodopa optimization as it provides the most robust tremor control in most patients 7, 8. If tremor persists despite adequate levodopa dosing:
- Assess tremor characteristics: Is it present during "off" periods (medication-responsive) or persistent despite medication (drug-resistant)?
- For off-period tremor: Add MAO-B inhibitors, COMT inhibitors, or dopamine agonists to extend levodopa effect
- For drug-resistant tremor: Consider propranolol or clozapine as adjuncts (though clozapine requires agranulocytosis monitoring) 7
- For refractory tremor: Refer for DBS evaluation, which effectively reduces tremor severity targeting STN, GPi, or VIM 2
Important Caveats
Mirtazapine carries significant risks in PD patients that outweigh any theoretical benefit:
- Somnolence occurs in 54% of patients, which could worsen PD-related fatigue 1
- Weight gain (≥7% body weight in 7.5% of patients) may complicate mobility 1
- Tremor is listed as an adverse effect in 2% of mirtazapine-treated patients 1
- QTc prolongation risk, particularly concerning in elderly PD patients with cardiovascular comorbidities 1
If a PD patient is already taking mirtazapine for depression or insomnia and experiences tremor improvement, this would be an incidental benefit rather than an indication to prescribe it specifically for tremor control.